varespladib has been researched along with tetrachloroisophthalonitrile in 1 studies
| Studies (varespladib) | Trials (varespladib) | Recent Studies (post-2010) (varespladib) | Studies (tetrachloroisophthalonitrile) | Trials (tetrachloroisophthalonitrile) | Recent Studies (post-2010) (tetrachloroisophthalonitrile) |
|---|---|---|---|---|---|
| 80 | 11 | 49 | 457 | 10 | 261 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akpunonu, PD; Bammigatti, C; Bhalla, A; Carter, RW; Gerardo, CJ; Kotehal, SD; Kumar, S; Lewin, MR; Manikath, N; Mukherjee, PP; Platts-Mills, TF; Samuel, SP; Shirazi, FM | 1 |
1 trial(s) available for varespladib and tetrachloroisophthalonitrile
| Article | Year |
|---|---|
The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming.
Topics: Clinical Trials, Phase II as Topic; Female; Humans; Male; Multicenter Studies as Topic; Phospholipases A2, Secretory; Randomized Controlled Trials as Topic; Snake Bites | 2022 |